secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2023-04-11T23:59:59+00:00
Accession:  0001193805-23-000532
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Meiji and CSL Seqirus to distribute Arcturus' COVID-19 vaccine ARCT-154 in Japan
--------------------------------------------------------------------------------

- Meiji Seika Pharma entered a distribution agreement with CSL Seqirus for Arcturus' COVID-19 vaccine candidate ARCT-154 in Japan.
- Phase III trial of ARCT-154 started Dec 12, 2022, targeting 780 participants; enrollment completed with 828 in Feb 2023.
- Arcturus has a Collaboration and License Agreement with CSL Seqirus since Dec 8, 2022 for global rights to self-amplifying mRNA vaccines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523000532/0001193805-23-000532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523000532/e618488_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-000532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer